Natick, United States
Sedec Therapeutics, founded in 2021, is a pioneering company within the Biotechnology industry. Focused on breakthrough therapeutics, the firm emphasizes the modulation of the immune cell system specifically targeting autoimmune diseases and cancer immunotherapies.
Leveraging advanced science in the protein palmitoylation/depalmitoylation pathway, Sedec’s innovative approach reflects its mission to translate unique biological advancements into a new class of patient therapeutics. Known for its slogan, "Leaders in protein palmitoylation pathway science," the company aims to redefine therapeutic solutions.
Headquartered in the United States, Sedec Therapeutics last secured a Seed Round investment led by Plaisance Capital Management on 01 January 2023. This investment underscores market confidence in their promising therapeutic ventures. Overall, Sedec represents a compelling opportunity for investors interested in innovative biotechnology solutions with significant growth potential.
